CL2014000175A1 - Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. - Google Patents

Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.

Info

Publication number: CL2014000175A1
Authority: CL; Chile
Prior art keywords: oxo; compound; cancer; benzazepin; butanamide
Prior art date: 2011-07-27

Application number

CL2014000175A

Other languages

English (en)

Inventor

Philip Arthur Hipskind

Gregory Alan Stephenson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-07-27

Filing date

2014-01-23

Publication date

2014-08-22

2014-01-23 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2014-08-22 Publication of CL2014000175A1 publication Critical patent/CL2014000175A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 title 1
206010006187 Breast cancer Diseases 0.000 title 1
208000026310 Breast neoplasm Diseases 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000011664 signaling Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Peptides Or Proteins (AREA)

CL2014000175A 2011-07-27 2014-01-23 Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros. CL2014000175A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161512016P	2011-07-27	2011-07-27
US201161560486P	2011-11-16	2011-11-16

Publications (1)

Publication Number	Publication Date
CL2014000175A1 true CL2014000175A1 (es)	2014-08-22

Family

ID=46598983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000175A CL2014000175A1 (es)	2011-07-27	2014-01-23	Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.

Country Status (36)

Country	Link
US (1)	US8569286B2 (es)
EP (1)	EP2736920B1 (es)
JP (1)	JP6027110B2 (es)
KR (1)	KR101578309B1 (es)
CN (1)	CN103732612B (es)
AP (1)	AP4080A (es)
AR (1)	AR087107A1 (es)
AU (1)	AU2012287251B2 (es)
BR (1)	BR112014001600B1 (es)
CA (1)	CA2841178C (es)
CL (1)	CL2014000175A1 (es)
CO (1)	CO6862159A2 (es)
CR (1)	CR20140036A (es)
CY (1)	CY1116645T1 (es)
DK (1)	DK2736920T3 (es)
DO (1)	DOP2014000011A (es)
EA (1)	EA023044B1 (es)
EC (1)	ECSP14013179A (es)
ES (1)	ES2544937T3 (es)
GT (1)	GT201400012A (es)
HR (1)	HRP20150771T1 (es)
HU (1)	HUE027534T2 (es)
IL (1)	IL229988A (es)
JO (1)	JO3148B1 (es)
MA (1)	MA35611B1 (es)
ME (1)	ME02171B (es)
MX (1)	MX356536B (es)
MY (1)	MY184303A (es)
PE (1)	PE20141061A1 (es)
PH (1)	PH12014500215B1 (es)
PL (1)	PL2736920T3 (es)
PT (1)	PT2736920E (es)
RS (1)	RS54135B1 (es)
SI (1)	SI2736920T1 (es)
TW (1)	TWI568730B (es)
WO (1)	WO2013016081A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10350216B2 (en)	2013-01-14	2019-07-16	The Trustees Of Columbia University In The City Of New York	Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CA2938626A1 (en)	2013-07-26	2015-01-29	John Rothman	Compositions to improve the therapeutic benefit of bisantrene
TWI704151B (zh)	2014-12-22	2020-09-11	美商美國禮來大藥廠	Ｅｒｋ抑制劑
TWI609687B (zh)	2015-04-14	2018-01-01	美國禮來大藥廠	平滑肌肉瘤之標靶性治療
JO3491B1 (ar)	2015-07-07	2020-07-05	Audion Therapeutics	مركبات مثبطة لإشارات مسار notch
IL287136B2 (en)	2016-02-05	2023-09-01	Denali Therapeutics Inc	Receptor inhibitors - interacting with protein kinase 1
CN120661674A (zh)	2016-03-15	2025-09-19	奥莱松基因组股份有限公司	用于治疗实体瘤的lsd1抑制剂的组合
AU2017249078B2 (en) *	2016-04-12	2022-10-20	Eli Lilly And Company	Combination therapy with notch and CDK4/6 inhibitors for the treatment of cancer
MX380780B (es) *	2016-04-12	2025-03-12	Lilly Co Eli	TERAPIA COMBINATORIA CON INHIBIDORES NOTCH Y PI3K/mTOR.
US10688104B2 (en)	2016-05-20	2020-06-23	Eli Lilly And Company	Combination therapy with Notch and PD-1 or PD-L1 inhibitors
CN109562114A (zh) *	2016-08-31	2019-04-02	伊莱利利公司	用于治疗实体瘤的给药方案
CA3039405A1 (en)	2016-10-12	2018-04-19	Eli Lilly And Company	Targeted treatment of mature t-cell lymphoma
HUE058802T2 (hu)	2016-12-09	2022-09-28	Denali Therapeutics Inc	RIPK1 inhibitorokként alkalmas vegyületek
CN110461335A (zh)	2017-02-17	2019-11-15	弗雷德哈钦森癌症研究中心	用于治疗bcma相关癌症和自身免疫性失调的联合疗法
KR102845789B1 (ko)	2017-11-01	2025-08-14	주노 쎄러퓨티크스 인코퍼레이티드	B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
US12193994B2 (en) *	2017-11-06	2025-01-14	Juno Therapeutics, Inc.	Combination of a cell therapy and a gamma secretase inhibitor
AU2019266150A1 (en) *	2018-05-06	2021-01-07	Ayala Pharmaceuticals Inc.	Combination compositions comprising bisfluoroalkyl-1,4- benzodiazepinone compounds and methods of use thereof
EP3860562A1 (en)	2018-10-02	2021-08-11	Frequency Therapeutics, Inc.	Pharmaceutical compositions comprising otic therapeutic agents and related methods
SG11202111191YA (en)	2019-04-08	2021-11-29	Frequency Therapeutics Inc	Combination of chir99021 and valproic acid for treating hearing loss
US11999750B2 (en)	2022-01-12	2024-06-04	Denali Therapeutics Inc.	Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP970705A2 (en) *	1996-12-23	1998-10-31	Warren J. Porter	CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
JP2002518481A (ja)	1998-06-22	2002-06-25	エランファーマシューティカルズ，インコーポレイテッド	β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
CA2325389A1 (en) *	1998-06-22	1999-12-29	James E. Audia	Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
HRP20050663A2 (en)	2003-02-04	2006-12-31	F. Hoffmann - La Roche Ag	Malonamide derivatives as gamma-secretase inhibitors
AU2004270361B2 (en)	2003-09-09	2009-06-25	F. Hoffmann-La Roche Ag	Malonamide derivatives blocking the activity of gama-secretase
WO2005040126A1 (en)	2003-10-06	2005-05-06	F. Hoffman-La Roche Ag	Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors
KR101169628B1 (ko)	2006-03-27	2012-07-30	에프. 호프만-라 로슈 아게	감마 세크레테아제 저해제로서의 말론아미드 유도체
WO2008092786A1 (en) *	2007-02-02	2008-08-07	F. Hoffmann-La Roche Ag	6-oxo-6,7-dihydro-5h-dibenzo[b,d]azepin-7-yl derivatives
KR20100101624A (ko)	2008-01-11	2010-09-17	에프. 호프만-라 로슈 아게	암 치료를 위한 감마-세크레타제 저해제의 용도
WO2011060051A1 (en) *	2009-11-12	2011-05-19	University Of Massachusetts	Methods for treating glioblastoma

2012
- 2012-07-10 JO JOP/2012/0190A patent/JO3148B1/ar active
- 2012-07-10 AR ARP120102486A patent/AR087107A1/es not_active Application Discontinuation
- 2012-07-13 TW TW101125459A patent/TWI568730B/zh active
- 2012-07-18 ES ES12741192.4T patent/ES2544937T3/es active Active
- 2012-07-18 BR BR112014001600-3A patent/BR112014001600B1/pt active IP Right Grant
- 2012-07-18 PE PE2014000129A patent/PE20141061A1/es active IP Right Grant
- 2012-07-18 EA EA201490161A patent/EA023044B1/ru not_active IP Right Cessation
- 2012-07-18 ME MEP-2015-105A patent/ME02171B/me unknown
- 2012-07-18 HR HRP20150771TT patent/HRP20150771T1/hr unknown
- 2012-07-18 EP EP12741192.4A patent/EP2736920B1/en active Active
- 2012-07-18 CA CA2841178A patent/CA2841178C/en active Active
- 2012-07-18 PH PH1/2014/500215A patent/PH12014500215B1/en unknown
- 2012-07-18 US US13/551,681 patent/US8569286B2/en active Active
- 2012-07-18 PT PT127411924T patent/PT2736920E/pt unknown
- 2012-07-18 CN CN201280037471.9A patent/CN103732612B/zh active Active
- 2012-07-18 JP JP2014522877A patent/JP6027110B2/ja active Active
- 2012-07-18 RS RS20150496A patent/RS54135B1/sr unknown
- 2012-07-18 HU HUE12741192A patent/HUE027534T2/en unknown
- 2012-07-18 WO PCT/US2012/047100 patent/WO2013016081A1/en not_active Ceased
- 2012-07-18 KR KR1020147001731A patent/KR101578309B1/ko active Active
- 2012-07-18 MX MX2014001084A patent/MX356536B/es active IP Right Grant
- 2012-07-18 MY MYPI2014700183A patent/MY184303A/en unknown
- 2012-07-18 DK DK12741192.4T patent/DK2736920T3/en active
- 2012-07-18 AU AU2012287251A patent/AU2012287251B2/en not_active Ceased
- 2012-07-18 SI SI201230246T patent/SI2736920T1/sl unknown
- 2012-07-18 AP AP2014007362A patent/AP4080A/en active
- 2012-07-18 PL PL12741192T patent/PL2736920T3/pl unknown
2013
- 2013-12-17 IL IL229988A patent/IL229988A/en active IP Right Grant
2014
- 2014-01-22 DO DO2014000011A patent/DOP2014000011A/es unknown
- 2014-01-22 MA MA36712A patent/MA35611B1/fr unknown
- 2014-01-23 CL CL2014000175A patent/CL2014000175A1/es unknown
- 2014-01-24 GT GT201400012A patent/GT201400012A/es unknown
- 2014-01-24 CO CO14014585A patent/CO6862159A2/es active IP Right Grant
- 2014-01-24 CR CR20140036A patent/CR20140036A/es unknown
- 2014-01-27 EC ECSP14013179 patent/ECSP14013179A/es unknown
2015
- 2015-08-25 CY CY20151100742T patent/CY1116645T1/el unknown

Also Published As

Publication number	Publication date
EP2736920B1 (en)	2015-07-01
HRP20150771T1 (hr)	2015-08-28
CN103732612A (zh)	2014-04-16
KR101578309B1 (ko)	2015-12-16
DOP2014000011A (es)	2014-07-31
BR112014001600B1 (pt)	2022-09-13
JO3148B1 (ar)	2017-09-20
US8569286B2 (en)	2013-10-29
CN103732612B (zh)	2015-09-23
SI2736920T1 (sl)	2015-08-31
MX2014001084A (es)	2014-02-27
AP4080A (en)	2017-03-29
PE20141061A1 (es)	2014-09-06
AR087107A1 (es)	2014-02-12
WO2013016081A1 (en)	2013-01-31
ME02171B (me)	2015-10-20
MX356536B (es)	2018-06-01
PL2736920T3 (pl)	2015-11-30
ECSP14013179A (es)	2014-03-31
EA201490161A1 (ru)	2014-04-30
AP2014007362A0 (en)	2014-01-31
RS54135B1 (sr)	2015-12-31
AU2012287251A1 (en)	2014-01-30
CA2841178C (en)	2016-12-20
MY184303A (en)	2021-03-31
EP2736920A1 (en)	2014-06-04
CR20140036A (es)	2014-03-21
IL229988A (en)	2017-07-31
AU2012287251B2 (en)	2015-05-14
MA35611B1 (fr)	2014-11-01
JP2014527042A (ja)	2014-10-09
KR20140026624A (ko)	2014-03-05
JP6027110B2 (ja)	2016-11-16
HK1194086A1 (en)	2014-10-10
PH12014500215A1 (en)	2014-03-17
PH12014500215B1 (en)	2018-09-07
CA2841178A1 (en)	2013-01-31
NZ618891A (en)	2015-12-24
DK2736920T3 (en)	2015-07-20
CY1116645T1 (el)	2017-03-15
US20130029972A1 (en)	2013-01-31
GT201400012A (es)	2014-07-16
ES2544937T3 (es)	2015-09-07
TW201315732A (zh)	2013-04-16
PT2736920E (pt)	2015-09-16
TWI568730B (zh)	2017-02-01
CO6862159A2 (es)	2014-02-10
HUE027534T2 (en)	2016-11-28
BR112014001600A2 (pt)	2017-02-21
EA023044B1 (ru)	2016-04-29

Publication	Publication Date	Title
CL2014000175A1 (es)	2014-08-22	Compuesto 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hidroxietil)-6-oxo-7h-pirido[2,3-d][3]benzazepin-7-il]amino]-1-metil-2-oxo-etil]butanamida, inhibidor de la señalizacion de la trayectoria notch; hidrato cristalino del compuesto; composicion farmaceutica; y su uso para el tratamiento de cancer tal como cancer de mama, entre otros.
CL2009000448A1 (es)	2009-11-27	Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
CL2014000511A1 (es)	2014-12-05	Compuestos derivados de quinazolina, inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7; proceso de preparacion; composiciones farmaceuticas que los contienen y el uso en el tratamiento y/o la prevencion de enfermedades tales como cancer.
MX2019003605A (es)	2019-06-17	Formas solidas de un inhibidor de cdk4/6 selectivo.
MY177344A (en)	2020-09-13	Compounds and their methods of use
CL2014000543A1 (es)	2014-09-26	Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer.
TN2014000016A1 (en)	2015-07-01	4 - piperidinyl compounds for use as tankyrase inhibitors
CO6700837A2 (es)	2013-06-28	Proceso de elaboración para derivados de prrimidina
CL2015002628A1 (es)	2016-08-26	Compuestos de heteroarilo y sus usos.
MD4820B1 (ro)	2022-08-31	Compuşi dihidroizochinolinonici substituiţi
JO3115B1 (ar)	2017-09-20	مركبات بيريدازينون واستخدامها كمثبطات daao
CL2014002386A1 (es)	2015-02-27	Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
PH12015501609A1 (en)	2015-10-05	Phenicol antibacterials
PH12018500071A1 (en)	2018-07-23	Plinabulin compositions
MX2014012477A (es)	2014-12-10	Inhibidores pirrolopirazona de tanquirasa.
PH12015502118A1 (en)	2016-01-25	Pyridin-4-yl derivatives
PE20130212A1 (es)	2013-03-09	Formas polimorficas de st-246 y metodos de preparacion
WO2014153495A9 (en)	2015-04-23	Novel stat3 inhibitors
CL2014002845A1 (es)	2015-01-30	Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
CL2014001323A1 (es)	2014-09-05	Compuestos derivados de 3-fenil-isoquinolin-1(2h)-ona, inhibidores de parp-1; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer.
CA2922375C (en)	2021-06-15	Alpha-tea salt forms: compositions and uses for treating disease
CL2015001881A1 (es)	2015-11-06	Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
WO2014115169A3 (en)	2016-02-25	Crizotinib solid dispersion
PH12015500282A1 (en)	2015-04-27	N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
NZ717880A (en)	2017-12-22	Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors